H.C. Wainwright analyst Mitchell Kapoor initiated coverage of Generate Biomedicines (GENB) with a Buy rating and $16 price target The stock has fallen over 20% even as GB-0895 advanced into two registrational severe uncontrolled asthma studies with a “product angle that could matter commercially,” the analyst tells investors in a research note. The firm thinks Generate’s setup is better than the stock implies.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GENB:
- Buy Rating on Generate Biomedicines Driven by Differentiated Pipeline, GB-0895 Asthma Opportunity, and AI-Enabled Protein Platform
- Generate Biomedicines: Differentiated AI-Driven Protein Platform with GB-0895 Asthma Lead and Emerging Oncology Upside Justifies Buy Rating
- Generate Biomedicines initiated with an Overweight at Cantor Fitzgerald
- Generate Biomedicines initiated with a Buy at Guggenheim
- Generate Biomedicines initiated with an Overweight at Morgan Stanley